GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
GENMAB A/S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.50+1.50 (+4.05%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
–
Operating margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 15.00 | – | |
| Interest coverage | – | 4.1× | – | |
| Capex to revenue | – | 3.0% | – | |
| Diluted shares | – | 66M | 63M |
Cash use needs five years of cash flow figures
Genmab A/S does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 1 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero–
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income– vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.25 → –
- No dilutionShare count did not rise65M → 63M
- Gross margin improvedGross margin up on the prior year95.42% → –
- More efficientAsset turnover rose0.61 → –